Skip to main content


Kala is a clinical-stage biopharmaceutical company

dedicated to the research, development, and commercialization of innovative therapies
for rare diseases of the eye.

Kala developed and launched two commercial products: EYSUVIS®, the first and only prescription therapy specially for the short-term management of the signs and symptoms of dry eye disease and INVELTYS®, the first twice-a-day corticosteroid indicated for the treatment of post-operative ocular inflammation and pain following ocular surgery. In July 2022, Kala announced
the completion of the sale of
its commercial products to Alcon Inc.

In November 2021, Kala acquired Combangio, Inc.
to further develop its lead asset, now known as KPI-012, a mesenchymal stem cell secretome (MSC-S). Kala is focused on developing biologic therapies utilizing this proprietary MSC-S platform.
Kala’s development pipeline includes KPI-012, in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, and KPI-014, its pre-clinical candidate for inherited retinal diseases. Kala is also evaluating KPI-012 for potential expansion to additional indications for rare front of the eye diseases, such as partial limbal stem cell deficiency and moderate-to-severe Sjögren's.

Please review our Privacy Statement(opens new window). This website uses cookies. By using our website without changing your cookie settings you agree to our use of cookies as described in our Privacy Statement(opens new window) .